Literature DB >> 24281769

Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Sachiko Seki1, Mutsunori Fujiwara, Masaaki Matsuura, Shuichi Fujita, Hisazumi Ikeda, Masahiro Umeda, Izumi Asahina, Tohru Ikeda.   

Abstract

Podoplanin, a type I transmembrane glycoprotein with an effect of platelet aggregation, has been reported to be one of the possible prognostic factors of oral squamous cell carcinoma (OSCC). However, the biological significance of podoplanin is largely unclear. The aim of this study was to develop a practical model for the prediction of prognosis using the grade of podoplanin expression, and also to evaluate the biological function of podoplanin. Eighty-two specimens of patients with previously untreated OSCC, who underwent either biopsy or surgery, were histopathologically and immunohistochemically analyzed. These 82 cases were composed of 66 well-differentiated, 10 moderately differentiated and 6 poorly differentiated OSCC. Podoplanin was successfully immunostained in 78 specimens, and was detected in most cases, but the frequency of positive cells varied. The prognosis of patients with more than 50 % podoplanin-positive tumor cells was significantly poorer than that of the other patients. Multivariate hazards regression analysis suggested that a linear combination of covariates, OSCC patients with more or less than 50 % podoplanin expression, age of more or less than 70 years old, mode of invasion and T3, T4 or T2 versus T1 of the UICC T-stage classification was the most effective model for evaluating the prognosis of OSCC patients. Additionally, podoplanin expression had a significant relationship to UICC clinical stage and the expression of Ki-67. An effective regression model using podoplanin expression was developed for evaluating the prognosis of OSCC and the biological significance of podoplanin was suggested to be associated with the growth and/or progression of OSCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24281769     DOI: 10.1007/s12253-013-9723-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Podoplanin is expressed in subsets of tumors of the central nervous system.

Authors:  Junji Shibahara; Takeshi Kashima; Yoshinao Kikuchi; Akiko Kunita; Masashi Fukayama
Journal:  Virchows Arch       Date:  2006-01-13       Impact factor: 4.064

2.  Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.

Authors:  Akinori Funayama; Jun Cheng; Satoshi Maruyama; Manabu Yamazaki; Takanori Kobayashi; Mei Syafriadi; Sukalyan Kundu; Susumu Shingaki; Chikara Saito; Takashi Saku
Journal:  Pathobiology       Date:  2011-05-26       Impact factor: 4.342

3.  Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome.

Authors:  Hisashi Tateyama; Hiroshi Sugiura; Chihiro Yamatani; Motoki Yano
Journal:  Hum Pathol       Date:  2011-01-14       Impact factor: 3.466

4.  High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis.

Authors:  Yongjun Xu; Akira Ogose; Hiroyuki Kawashima; Tetsuo Hotta; Takashi Ariizumi; Guidong Li; Hajime Umezu; Naoto Endo
Journal:  Oncol Rep       Date:  2011-01-13       Impact factor: 3.906

5.  Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

Authors:  Leah N Cueni; Ivan Hegyi; Jay W Shin; Andrea Albinger-Hegyi; Silke Gruber; Rainer Kunstfeld; Holger Moch; Michael Detmar
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

6.  The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma.

Authors:  Fatemeh Mashhadiabbas; Faranak Mahjour; Seyyed Babak Mahjour; Forouzandeh Fereidooni; Fatemeh Sadat Hosseini
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-08

7.  Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study.

Authors:  L Tong; S Yuan; F Feng; H Zhang
Journal:  Dis Esophagus       Date:  2011-09-02       Impact factor: 3.429

8.  Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.

Authors:  Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

9.  Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.

Authors:  Diana M Padgett; Helen P Cathro; Mark R Wick; Stacey E Mills
Journal:  Am J Surg Pathol       Date:  2008-01       Impact factor: 6.394

10.  Podoplanin in the development and progression of oral cavity cancer: a preliminary study.

Authors:  F N Bartuli; F Luciani; F Caddeo; S Compagni; P Piva; L Ottria; C Arcuri
Journal:  Oral Implantol (Rome)       Date:  2012-11-16
View more
  10 in total

1.  CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

Authors:  Junhee Park; Xianglan Zhang; Sun Kyoung Lee; Na-Young Song; Seung Hwa Son; Ki Rim Kim; Jae Hoon Shim; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

2.  Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma.

Authors:  Tohru Ikeda; Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Yuu Ozaki-Honda; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

3.  Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma.

Authors:  Woo-Young Sun; Woo-Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2015-12-30

4.  Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck.

Authors:  Stefan Huttenlocher; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Christoph Thorns; Katrin Hasselbacher; Barbara Wollenberg; Steven E Schild; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2014-06-14       Impact factor: 3.621

5.  Prognostic Prediction of Oral Squamous Cell Carcinoma by E-Cadherin and N-Cadherin Expression in Overall Cells in Tumor Nests or Tumor Cells at the Invasive Front.

Authors:  Yuu Ozaki-Honda; Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Takao Ayuse; Tohru Ikeda
Journal:  Cancer Microenviron       Date:  2017-11-02

6.  Expression of Podoplanin in Laryngeal Squamous Cell Carcinoma and Dysplasia.

Authors:  Badawia Bayoumy Ibrahim; Mostafa Mohamed Salem; Rasha Ahmed Khairy; Reema Abdul Rahman Al Gunaid
Journal:  J Clin Diagn Res       Date:  2017-05-01

7.  Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas.

Authors:  Emily Van de Laar; Monica Clifford; Stefan Hasenoeder; Bo Ram Kim; Dennis Wang; Sharon Lee; Josh Paterson; Nancy M Vu; Thomas K Waddell; Shaf Keshavjee; Ming-Sound Tsao; Laurie Ailles; Nadeem Moghal
Journal:  Respir Res       Date:  2014-12-31

Review 8.  Podoplanin: An emerging cancer biomarker and therapeutic target.

Authors:  Harini Krishnan; Julie Rayes; Tomoyuki Miyashita; Genichiro Ishii; Edward P Retzbach; Stephanie A Sheehan; Ai Takemoto; Yao-Wen Chang; Kazue Yoneda; Jun Asai; Lasse Jensen; Lushun Chalise; Atsushi Natsume; Gary S Goldberg
Journal:  Cancer Sci       Date:  2018-05       Impact factor: 6.716

9.  Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.

Authors:  Hitomi Sudo; Atsushi B Tsuji; Aya Sugyo; Tsuneo Saga; Mika K Kaneko; Yukinari Kato; Tatsuya Higashi
Journal:  Cancer Sci       Date:  2019-03-12       Impact factor: 6.716

10.  Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.

Authors:  Yao-Wen Chang; Pei-Wen Hsieh; Yu-Tsui Chang; Meng-Hong Lu; Tur-Fu Huang; Kowit-Yu Chong; Hsiang-Ruei Liao; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Oncotarget       Date:  2015-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.